Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Streamline Eco-friendliness in Your Volvo XC40 - 2Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- 3Fiber is something most people could use more of. But experts advise caution with 'fibermaxxing'
- 4Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- 5Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- 6 Agreeable Earphones To Wear
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Vote In favor of Your Favored Pizza Cover
- Defence chiefs of Thailand and Cambodia to discuss ceasefire
- The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
